Targeting USP22 reprograms the tumor microenvironment and sensitizes KRAS/p53-driven lung cancer to anti-PD-1 immunotherapy - Research Paper
Favorite
Share
More Options
25

Open in WPS to view all 25 pages
This document is user-generated content (UGC). WPS Office is not responsible for its accuracy or copyright. If you believe this content violates your rights, please use the button.
